Acadia Pharmaceuticals Inc. (ACAD)
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript
Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.16 per share a year ago.
ACADIA Pharmaceuticals Q2 Earnings Call Highlights
ACADIA Pharmaceuticals NASDAQ: ACAD reported second-quarter 2026 revenue of $308 million, representing 17% year-over-year growth on an adjusted basis, as sales of its Rett syndrome therapy DAYBUE and Parkinson's disease psychosis treatment NUPLAZID increased.
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.
Wall Street Analysts Believe Acadia (ACAD) Could Rally 30.89%: Here's is How to Trade
The mean of analysts' price targets for Acadia (ACAD) points to a 30.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ACAD Stock Up as CHMP Backs Daybu for EU Approval in Rett Syndrome
Acadia stock jumps 7% as CHMP backs Daybu for EU approval in Rett syndrome, with the European Commission set to make a final decision in the coming months.
Acadia Pharmaceuticals: Steady Commercial Progress, Remlifanserin Data In Focus
Acadia Pharmaceuticals demonstrates steady commercial growth with Nuplazid and Daybue, supported by a recent positive CHMP opinion for Daybue in Europe. Remlifanserin's upcoming phase 2 readout in Alzheimer's disease psychosis is a high-risk, high-reward catalyst not priced into ACAD's current valuation. I maintain a bullish outlook on ACAD based on commercial products Nuplazid and Daybue, but above-average returns depend on pipeline or business development success.
Strength Seen in Acadia (ACAD): Can Its 6.8% Jump Turn into More Strength?
Acadia (ACAD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Acadia (ACAD) Down 3.7% Since Last Earnings Report: Can It Rebound?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
ACADIA Pharmaceuticals Spotlights Alzheimer's Psychosis Pipeline, NUPLAZID and DAYBUE Growth
ACADIA Pharmaceuticals NASDAQ: ACAD executives used an RBC Capital Markets investor session to outline the company's clinical rationale for remlifanserin in Alzheimer's disease psychosis, provide updates on commercial trends for NUPLAZID and DAYBUE, and discuss selected pipeline and business development priorities.
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Bank of America Global Healthcare Conference 2026 Transcript
